Dr. Wael M. ElShamy

Associate Professor
San Diego Biomedical Res Institute, California

Highest Degree
Ph.D. in Medical Biochemistry and Biophysics from Karolinska Institutet, Sweden

My URL
https://livedna.org/20.23670

Share this Profile

Area of Interest:

Biomedical Sciences
Cancer Biology
Neurobiology
Biochemistry
Pathology

Selected Publications

  1. Sinha, A., B.T. Paul, L.M. Sullivan, H. Sims and A. El Bastawisy et al., 2017. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget, 8: 10114-10135.
    Direct Link  |  

  2. Ryan, D., A. Sinha, D. Bogan, J. Davies, J. Koziol and W.M. ElShamy, 2017. Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment. Oncotarget, Vol. 8. .
    Direct Link  |  

  3. Bogan, D., A. Bahnassy, A. El-Bastawisy, H. Yousef, A.R. Zekri and W.M. ElShamy, 2017. Role of BRCA1-IRIS in the development of triple negative breast cancers in Egyptian women: Possible association with TNBC early lesion. BMC Cancer, Vol. 15. 10.1186/s12885-017-3283-8.
    CrossRef  |  

  4. ElShmay, W.M., 2016. The protective effect of longer duration of breastfeeding against pregnancy-associated triple negative breast cancer. Oncotarget, 7: 53941-53950.
    Direct Link  |  

  5. ElShamy, W.M., A. Sinha and N. Said, 2016. Aggressiveness niche: Can it be the foster ground for cancer metastasis precursors? Stem Cells Int., 10.1155/2016/4829106.
    CrossRef  |  Direct Link  |  

  6. ElShamy, W.M., 2016. The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression. Oncoscience, 3: 145-146.
    Direct Link  |  

  7. Ananthula, S., A. Sinha, M. El Gassim, S. Batth and G.D. Marshall et al., 2016. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget, 7: 20869-20889.
    CrossRef  |  Direct Link  |  

  8. Paul, B.T., Z. Blanchard, M. Ridgway and W.M. ElShamy, 2015. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene, 34: 3036-3052.
    CrossRef  |  Direct Link  |  

  9. Blanchard, Z., B.T. Paul, B. Craft and W.M. ElShamy, 2015. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res., Vol. 17. 10.1186/s13058-014-0512-9.
    CrossRef  |  Direct Link  |  

  10. Blanchard, Z., N. Mullins, P. Ellipeddi, J.M. Lage and S. McKinney et al., 2014. Geminin overexpression promotes imatinib sensitive breast cancer: A novel treatment approach for aggressive breast cancers, including a subset of triple negative. Plos One, Vol. 9. 10.1371/journal.pone.0095663.
    CrossRef  |  Direct Link  |  

  11. ElShamy, W.M. and R.J. Duhe, 2013. Overview: Cellular plasticity, cancer stem cells and metastasis. Cancer Lett., 341: 2-8.

  12. Shimizu, Y., N. Mullins, Z. Blanchard and W.M. ElShamy, 2012. BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget, 3: 299-313.
    Direct Link  |  

  13. Shimizu, Y., H. Luk, D. Horio, P. Miron and M. Griswold et al., 2012. BRCA1-IRIS overexpression promotes formation of aggressive breast cancers. PLoS One, Vol. 7. 10.1371/journal.pone.0034102.
    CrossRef  |  Direct Link  |  

  14. Gardner, L., R. Malik, Y. Shimizu, N. Mullins and W.M. ElShamy, 2011. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells. Breast Cancer Res., Vol. 13. 10.1186/bcr2884.
    CrossRef  |  Direct Link  |  

  15. Blanchard, Z., R. Malik, N. Mullins, C. Maric and H. Luk et al., 2011. Geminin overexpression induces mammary tumors via suppressing cytokinesis. Oncotarget, 2: 1011-1027.
    Direct Link  |  

  16. Elshamy, WM., 2010. Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression. Hawaii Med. J., 69: 200-201.

  17. Chock, K.L., J.M. Allison, Y. Shimizu and W.M. ElShamy, 2010. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res., 70: 8782-8791.

  18. Chock, K., J.M.S. Allison and W.M. ElShamy, 2010. BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells. Oncogene, 29: 5274-5285.
    CrossRef  |  Direct Link  |  

  19. Pujana, M., J.D. Han, L. Starita, M. Tewari and J. Ahn et al., 2007. A breast cancer network model Establishes a link between BRCA1 and centrosome dysfunction. Nature Genet., 39: 1338-1349.

  20. Hao, L. and W.M. ElShamy, 2007. BRCA1‐IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. Int. J. Cancer, 121: 39-46.
    Direct Link  |  

  21. Nakuci, E., S. Mahner, J. DiRenzo and W.M. ElShamy, 2006. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. Exp. Cell Res., 312: 3120-3131.
    CrossRef  |  Direct Link  |  

  22. Nakuci, E., M. Xu, M.A. Pujana, J. Valls and W.M. ElShamy, 2006. Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis. Int. J. Biochem. Cell Biol., 38: 1207-1220.
    CrossRef  |  Direct Link  |  

  23. ElShamy, W., 2005. Epithelial to mesenchymal transition, cell surface receptors activation and intracellular communications in cancer metastasis. Cancer Ther., 3: 443-460.

  24. ElShamy, W.M. and D.M. Livingston, 2004. Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biol., 6: 954-967.
    CrossRef  |  Direct Link  |  

  25. Avni, D., H. Yang, F. Martelli, F. Hofmann and W.M. ElShamy et al., 2003. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol. Cell, 12: 735-746.
    CrossRef  |  Direct Link  |  

  26. ElShamy, W.M., L.K. Fridvall and P. Ernfors, 1998. Growth arrest failure, G1 restriction point override and S phase death of sensory precursor cells in the absence of neurotrophin-3. Neuron, 21: 1003-1015.
    CrossRef  |  Direct Link  |  

  27. Nosrat, C.A., J. Blomlof, W.M. ElShamy, P. Ernfors and L. Olson, 1997. Lingual deficits in BDNF and NT3 mutant mice leading to gustatory and somatosensory disturbances, respectively. Development, 124: 1333-1342.
    Direct Link  |  

  28. Naveilhan, P., W.M. ElShamy and P. Ernfors, 1997. Differential regulation of mRNAs for GDNF and its receptors Ret and GDNFRα after sciatic nerve lesion in the mouse. Eur. J. Neurosci., 9: 1450-1460.
    CrossRef  |  Direct Link  |  

  29. ElShamy, W.M. and P. Ernfors, 1997. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4 complement and cooperate with each other sequentially during visceral neuron development. J. Neurosci., 17: 8667-8675.
    CrossRef  |  Direct Link  |  

  30. Ernfors, P., M.L. Duan, W.M. Elshamy and B. Canlon, 1996. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nature Med., 2: 463-467.
    CrossRef  |  Direct Link  |  

  31. Elshamy, W.M. and P. Ernfors, 1996. Requirement of neurotrophin-3 for the survival of proliferating trigeminal ganglion progenitor cells. Development, 122: 2405-2414.
    Direct Link  |  

  32. ElShamy, W.M., S. Linnarsson, K.F. Lee, R. Jaenisch and P. Ernfors, 1996. Prenatal and postnatal requirements of NT-3 for sympathetic neuroblast survival and innervation of specific targets. Development, 122: 491-500.
    Direct Link  |  

  33. ElShamy, W.M. and P. Ernfors, 1996. A local action of neurotrophin-3 prevents the death of proliferating sensory neuron precursor cells. Neuron, 16: 963-972.
    CrossRef  |  Direct Link  |  

  34. Walum, E., G. Eriksson, A. Peterson, E. Holme, N.G. Larsson, C. Eriksson and W. El‐Shamy, 1995. Use of primary cultures and continuous cell lines to study effects on astrocytic regulatory functions. Clin. Exper. Pharmacol. Physiol., 22: 284-287.
    CrossRef  |  Direct Link  |  
Member since April, 2018